McKechnie Duncan
EVP, Chief Commercial Officer
McKechnie Duncan has filed 8 SEC Form 4 filings (12 transaction rows) across 1 company, with disclosures dating back to 2026. 8 of those filings fall inside the rolling window. Most recent filing: Jul 7, 2026.
On the most recent filing, McKechnie Duncan is listed as EVP, Chief Commercial Officer at VERTEX PHARMACEUTICALS INC / MA. Inside the rolling window, McKechnie Duncan reported no open-market purchases and 4 open-market sales totaling $5.7M in VRTX. The largest disclosed transaction in the window is a sale of 4,910 VRTX shares on Feb 25, 2026, worth $2.4M.
Companies traded
Other insiders at VRTX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$5.7M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has McKechnie Duncan made?
McKechnie Duncan has filed 8 SEC Form 4 filings (12 transaction rows) across 1 company since 2026.
Which companies does McKechnie Duncan trade?
McKechnie Duncan has filed SEC Form 4 disclosures for 1 company, including VRTX.
When was McKechnie Duncan's most recent SEC Form 4 filing?
McKechnie Duncan's most recent SEC Form 4 filing on Tracefour is dated Jul 7, 2026.
What is McKechnie Duncan's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, McKechnie Duncan is listed as EVP, Chief Commercial Officer.
What is McKechnie Duncan's total buy and sell value in the current window?
Inside the rolling retention window, McKechnie Duncan bought $0 and sold $5.7M based on SEC Form 4 filings.
What was McKechnie Duncan's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 4,910 VRTX shares on 2026-02-25, worth $2.4M, per SEC Form 4 filings.